17 research outputs found

    Therapeutic effects of pyrrolidine dithiocarbamate on acute lung injury in rabbits

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) is an early characteristic of multiple organ dysfunction, responsible for high mortality and poor prognosis in patients. The present study aims to evaluate therapeutic effects and mechanisms of pyrrolidine dithiocarbamate (PDTC) on ALI.</p> <p>Methods</p> <p>Alveolar-arterial oxygen difference, lung tissue edema and compromise, NF-κB activation in polymorphonuclear neutrophil (PMN), and systemic levels of tumor necrosis factor-alpha (TNFa) and intercellular adhesion molecule-1 (ICAM-1) in rabbits induced by the intravenous administration of lipopolysaccharide (LPS) and treated with PDTC. Production of TNFa and IL-8, activation of Cathepsin G, and PMNs adhesion were also measured.</p> <p>Results</p> <p>The intravenous administration of PDTC had partial therapeutic effects on endotoxemia-induced lung tissue edema and damage, neutrophil influx to the lung, alveolar-capillary barrier dysfunction, and high systemic levels of TNFa and ICAM-1 as well as over-activation of NF-κB. PDTC could directly and partially inhibit LPS-induced TNFa hyper-production and over-activities of Cathepsin G. Such inhibitory effects of PDTC were related to the various stimuli and enhanced through combination with PI3K inhibitor.</p> <p>Conclusion</p> <p>NF-κB signal pathway could be one of targeting molecules and the combination with other signal pathway inhibitors may be an alternative of therapeutic strategies for ALI/ARDS.</p

    Age-based disparities in end-of-life decisions in Belgium: a population-based death certificate survey

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>A growing body of scientific research is suggesting that end-of-life care and decision making may differ between age groups and that elderly patients may be the most vulnerable to exclusion of due care at the end of life. This study investigates age-related disparities in the rate of end-of-life decisions with a possible or certain life shortening effect (ELDs) and in the preceding decision making process in Flanders, Belgium in 2007, where euthanasia was legalised in 2002. Comparing with data from an identical survey in 1998 we also study the plausibility of the ‘slippery slope’ hypothesis which predicts a rise in the rate of administration of life ending drugs without patient request, especially among elderly patients, in countries where euthanasia is legal.</p> <p>Method</p> <p>We performed a post-mortem survey among physicians certifying a large representative sample (n = 6927) of death certificates in 2007, identical to a 1998 survey. Response rate was 58.4%.</p> <p>Results</p> <p>While the rates of non-treatment decisions (NTD) and administration of life ending drugs without explicit request (LAWER) did not differ between age groups, the use of intensified alleviation of pain and symptoms (APS) and euthanasia/assisted suicide (EAS), as well as the proportion of euthanasia requests granted, was bivariately and negatively associated with patient age. Multivariate analysis showed no significant effects of age on ELD rates. Older patients were less often included in decision making for APS and more often deemed lacking in capacity than were younger patients. Comparison with 1998 showed a decrease in the rate of LAWER in all age groups except in the 80+ age group where the rate was stagnant.</p> <p>Conclusion</p> <p>Age is not a determining factor in the rate of end-of-life decisions, but is in decision making as patient inclusion rates decrease with old age. Our results suggest there is a need to focus advance care planning initiatives on elderly patients. The slippery slope hypothesis cannot be confirmed either in general or among older people, as since the euthanasia law fewer LAWER cases were found.</p

    Estimating Long-Term Survival of Critically Ill Patients: The PREDICT Model

    Get PDF
    BACKGROUND: Long-term survival outcome of critically ill patients is important in assessing effectiveness of new treatments and making treatment decisions. We developed a prognostic model for estimation of long-term survival of critically ill patients. METHODOLOGY AND PRINCIPAL FINDINGS: This was a retrospective linked data cohort study involving 11,930 critically ill patients who survived more than 5 days in a university teaching hospital in Western Australia. Older age, male gender, co-morbidities, severe acute illness as measured by Acute Physiology and Chronic Health Evaluation II predicted mortality, and more days of vasopressor or inotropic support, mechanical ventilation, and hemofiltration within the first 5 days of intensive care unit admission were associated with a worse long-term survival up to 15 years after the onset of critical illness. Among these seven pre-selected predictors, age (explained 50% of the variability of the model, hazard ratio [HR] between 80 and 60 years old = 1.95) and co-morbidity (explained 27% of the variability, HR between Charlson co-morbidity index 5 and 0 = 2.15) were the most important determinants. A nomogram based on the pre-selected predictors is provided to allow estimation of the median survival time and also the 1-year, 3-year, 5-year, 10-year, and 15-year survival probabilities for a patient. The discrimination (adjusted c-index = 0.757, 95% confidence interval 0.745-0.769) and calibration of this prognostic model were acceptable. SIGNIFICANCE: Age, gender, co-morbidities, severity of acute illness, and the intensity and duration of intensive care therapy can be used to estimate long-term survival of critically ill patients. Age and co-morbidity are the most important determinants of long-term prognosis of critically ill patients

    Cyanobacterial lipopolysaccharides and human health – a review

    Get PDF
    Cyanobacterial lipopolysaccharide/s (LPS) are frequently cited in the cyanobacteria literature as toxins responsible for a variety of heath effects in humans, from skin rashes to gastrointestinal, respiratory and allergic reactions. The attribution of toxic properties to cyanobacterial LPS dates from the 1970s, when it was thought that lipid A, the toxic moiety of LPS, was structurally and functionally conserved across all Gram-negative bacteria. However, more recent research has shown that this is not the case, and lipid A structures are now known to be very different, expressing properties ranging from LPS agonists, through weak endotoxicity to LPS antagonists. Although cyanobacterial LPS is widely cited as a putative toxin, most of the small number of formal research reports describe cyanobacterial LPS as weakly toxic compared to LPS from the Enterobacteriaceae. We systematically reviewed the literature on cyanobacterial LPS, and also examined the much lager body of literature relating to heterotrophic bacterial LPS and the atypical lipid A structures of some photosynthetic bacteria. While the literature on the biological activity of heterotrophic bacterial LPS is overwhelmingly large and therefore difficult to review for the purposes of exclusion, we were unable to find a convincing body of evidence to suggest that heterotrophic bacterial LPS, in the absence of other virulence factors, is responsible for acute gastrointestinal, dermatological or allergic reactions via natural exposure routes in humans. There is a danger that initial speculation about cyanobacterial LPS may evolve into orthodoxy without basis in research findings. No cyanobacterial lipid A structures have been described and published to date, so a recommendation is made that cyanobacteriologists should not continue to attribute such a diverse range of clinical symptoms to cyanobacterial LPS without research confirmation

    Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008

    Get PDF
    SCOPUS: ar.jinfo:eu-repo/semantics/publishe

    Iron Behaving Badly: Inappropriate Iron Chelation as a Major Contributor to the Aetiology of Vascular and Other Progressive Inflammatory and Degenerative Diseases

    Get PDF
    The production of peroxide and superoxide is an inevitable consequence of aerobic metabolism, and while these particular "reactive oxygen species" (ROSs) can exhibit a number of biological effects, they are not of themselves excessively reactive and thus they are not especially damaging at physiological concentrations. However, their reactions with poorly liganded iron species can lead to the catalytic production of the very reactive and dangerous hydroxyl radical, which is exceptionally damaging, and a major cause of chronic inflammation. We review the considerable and wide-ranging evidence for the involvement of this combination of (su)peroxide and poorly liganded iron in a large number of physiological and indeed pathological processes and inflammatory disorders, especially those involving the progressive degradation of cellular and organismal performance. These diseases share a great many similarities and thus might be considered to have a common cause (i.e. iron-catalysed free radical and especially hydroxyl radical generation). The studies reviewed include those focused on a series of cardiovascular, metabolic and neurological diseases, where iron can be found at the sites of plaques and lesions, as well as studies showing the significance of iron to aging and longevity. The effective chelation of iron by natural or synthetic ligands is thus of major physiological (and potentially therapeutic) importance. As systems properties, we need to recognise that physiological observables have multiple molecular causes, and studying them in isolation leads to inconsistent patterns of apparent causality when it is the simultaneous combination of multiple factors that is responsible. This explains, for instance, the decidedly mixed effects of antioxidants that have been observed, etc...Comment: 159 pages, including 9 Figs and 2184 reference

    Profilaxia medicamentosa da trombose venosa profunda em pacientes submetidos à cirurgia do trauma em um hospital universitário Drug prophylaxis of deep venous thrombosis in patients submitted to trauma surgery in a university hospital

    No full text
    CONTEXTO: Anualmente, milhões de pessoas são vítimas de trauma no mundo. Além de suas consequências sociais e econômicas, muitos dos pacientes necessitam de tratamento cirúrgico, gerando, portanto, maiores riscos à vida. O tromboembolismo venoso, consequência da trombose venosa profunda, é uma importante causa de morbimortalidade em pós-operatórios e pode ser evitado com profilaxia adequada. OBJETIVO: Avaliar a utilização da profilaxia medicamentosa para trombose venosa profunda em pacientes submetidos à cirurgia do trauma de emergência, em um hospital-escola. MÉTODOS: Estudo transversal analítico, com 153 pacientes internados no Hospital Universitário Cajuru, em Curitiba, no Paraná, durante dois meses. Foram analisados prospectivamente prontuários de pacientes que necessitaram de cirurgia devido a trauma. O estudo incluiu pacientes classificados como alto e médio risco para trombose venosa profunda e avaliou-se a realização, ou não, da profilaxia medicamentosa. A análise estatística foi feita de forma descritiva. RESULTADOS: Dos 153 pacientes incluídos no estudo, 99 (64,7%) foram classificados como alto risco para trombose venosa e 54 (35,3%) como médio, sendo que 144 (94%) não receberam profilaxia medicamentosa. Dos nove (6%) pacientes que receberam profilaxia medicamentosa, um foi estratificado como médio risco e os outros oito de alto risco. Dos pacientes que receberam profilaxia, em apenas quatro a orientação foi adequada. CONCLUSÕES: A profilaxia para trombose venosa não é realizada de maneira rotineira nos pacientes de médio e alto risco para trombose venosa profunda que são submetidos à cirurgia do trauma e, quando realizada, muitas vezes é inadequada.<br>BACKGROUND: Annually, millions of people are victims of trauma around the world. Besides the social and economic consequences caused by it, many of these patients need surgical treatment, thus generating greater risk to life. Venous thromboembolism, a consequence of deep vein thrombosis, represents a major cause of the morbidity and mortality in postoperative state, and it could be avoided with adequate prophylaxis. OBJECTIVE: To evaluate the use of chemoprophylaxis for deep vein thrombosis, in patients undergoing emergency trauma surgery in a teaching hospital. METHODS: A cross-sectional analytic study was conducted with 153 patients admitted to Cajuru University Hospital, in Curitiba, Paraná, in a two-month period. Records of patients who required surgery due to trauma were prospectively analyzed. The study included those classified as high and medium risk for deep vein thrombosis. Then, it was identified whether or not the drug prophylaxis was used. A statistical analysis was descriptively performed. RESULTS: Of the 153 patients included, 99 (64.7%) were classified as high risk for deep vein thrombosis and 54 (35.3%) as medium risk. Of the total, 144 (94%) did not receive prophylaxis and nine (6%) did. On those who received prophylaxis, only four patients received the adequate. CONCLUSIONS: Prophylaxis of venous thrombosis disease is not performed routinely in patients of medium and high risk of developing deep vein thrombosis, who underwent trauma surgery. And, when performed, it is often inappropriate
    corecore